Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Arthritis Study of Certolizumab Pegol (PASCAL)
RBR-6s67w4Phase 3Completed
- Sponsor
- UCB
- Start
- Mar 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in juvenile idiopathic arthritis (JIA), sponsored by UCB. Started Mar 2012; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on RBR-6s67w4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6s67w4.